ZMapp is produced with tobacco-plant based mAbs. (Picture: Kevin Bercaw)

CMO Kentucky Bioprocessing grows Ebola mAb from tobacco

By Fiona BARRY

ZMapp, the experimental Ebola therapy given to a handful of infected patients in West Africa, is being produced in tobacco plants for Mapp Biopharmaceutical by CMO Kentucky Bioprocessing in collaboration with drugmaker Defyrus.

 Spain announced that it imported a few doses of Mapp Biopharmaceutical’s ZMapp to treat a priest who was brought from Liberia to Madrid

Biopharma companies race to develop Ebola vaccine

By Zachary Brennan

As the death toll from the world’s most expansive Ebola outbreak nears 1,000, multiple companies are stepping up efforts to bring antibodies and other vaccines to human trials, though none seem likely to be ready until 2015 at the earliest.